Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
Sofia, Bulgaria, June 5, 2023 - Pursuant to the requirements of Article 100t of the Securities Act, Sopharma AD announces that at its meeting the Board of Directors of the Company resolved to increase the capital on the condition that the shares from the increase are subscribed by the warrant holders, based on a resolution legally adopted at the General Meeting of Warrantholders (GMW) on June 2, 2023. This notification is not a notification pursuant to art. 89t of the Law on Public Offering of Securities.
Sofia, Bulgaria, June 2, 2023 – In accordance with the requirements of art. 115c, para. 4 of LPOS “Sopharma” AD notifies all shareholders of the Company about the decision of the AGM of “Sopharma” AD that took place on June 2, 2023 regarding the amount and type of dividend distributed and the terms and conditions for its distribution:
The AGM approves the proposal by the Board of Directors for the distribution of gross dividend at the amount of 0.60 BGN /sixty stotinki / per share.
Sofia, Bulgaria, June 1, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD notifies that at its meeting the Board of Directors decided to conduct a detailed analysis of potential opportunities for acquisition of shares in the capital of companies engaged in the production and/or marketing of medicinal products, food supplements, medical devices and/or other goods of importance to human health on the territory of the Republic of Serbia.